{"name":"Cancer Research UK","slug":"cancer-research-uk","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"AST-VAC2","genericName":"AST-VAC2","slug":"ast-vac2","indication":"Other","status":"phase_1"},{"name":"HMBD-001","genericName":"HMBD-001","slug":"hmbd-001","indication":"Other","status":"phase_1"},{"name":"ALETA-001","genericName":"ALETA-001","slug":"aleta-001","indication":"Other","status":"phase_1"},{"name":"AT13148","genericName":"AT13148","slug":"at13148","indication":"Other","status":"phase_1"},{"name":"DI-B4","genericName":"DI-B4","slug":"di-b4","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"releasing hormone agonist therapy","genericName":"releasing hormone agonist therapy","slug":"releasing-hormone-agonist-therapy","indication":"Prostate cancer","status":"phase_3"}]}],"pipeline":[{"name":"AST-VAC2","genericName":"AST-VAC2","slug":"ast-vac2","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"HMBD-001","genericName":"HMBD-001","slug":"hmbd-001","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALETA-001","genericName":"ALETA-001","slug":"aleta-001","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AT13148","genericName":"AT13148","slug":"at13148","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"DI-B4","genericName":"DI-B4","slug":"di-b4","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"releasing hormone agonist therapy","genericName":"releasing hormone agonist therapy","slug":"releasing-hormone-agonist-therapy","phase":"phase_3","mechanism":"Releasing hormone agonist therapy works by mimicking the action of natural hormones to stimulate the release of other hormones.","indications":["Prostate cancer","Breast cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPajI2SkF6NVpZck1qQVdfUXlqV1YzTEtRaWdya3JxOUFBZ1Q2TktLTU40SWFSQ09iOF9ubnNvcDZLTXlsRVBXbjYyNTZBZTdZR3BtNGd3NW1JUWV3cUh2SmFsTC1uajdONk1BT2JpcGotaWxfRlBTdHRZTlVsOGpib1VqczZ4OFE?oc=5","date":"2026-04-02","type":"deal","source":"Mirage News","summary":"NHS, UK Firms Gain From US Pharma Access Deal - Mirage News","headline":"NHS, UK Firms Gain From US Pharma Access Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNS3hhbV82aGNaSExWM2NLX1FxeEhHaG51dU8xMm40SFN5M2pkWjhSZzMtaDZuQm1zUTgyV040eU9hemZJWXB6ZUZJN29PRUJ4dlJjRHFjNFhZZmZNV1ZwMHF1d0dWMGFxWVFSeHlZQjZ5NEphTEJvU2pqbGttZWpySGJqSWJfbHBld3RlODc3NFF3dWhGOUE?oc=5","date":"2026-03-04","type":"pipeline","source":"pharmaphorum","summary":"Five projects share £100m UK-US Cancer Grand Challenges fund - pharmaphorum","headline":"Five projects share £100m UK-US Cancer Grand Challenges fund","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9kZ3U5dV96Vl9BSXgzUzhhSWIzV2ExTExMRU9ocGYxUUNOMC1aWndDRjQ2LWRfU2xpMG9ETXFrSzh1NGw1dVNKM0V3TEJKd3NJckxQWDhhbjRuTEdxWUNYUzlGd1ktM25ybkVfMWR2SmI0clJIMDUwOWYwRWNnQQ?oc=5","date":"2025-12-01","type":"pipeline","source":"pharmaphorum","summary":"Limited prostate cancer screening backed in UK - pharmaphorum","headline":"Limited prostate cancer screening backed in UK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPUmhSNVQzWDdaaFV3NUxiLXpvZm5zSFh3d0YzV3Bkc3ZhR2k5b0JYbTk3a3lNTVZkYVhJMEhyOTBZODRmUWdlcWMzMGxJZHBobG9udzcxZnlJVnBpMXpZdnk2Wk5STDZINWVGd0NmLUxIbUtyYnhnNHdsanBkTFpNRF8tbl9FeXN6a3pNVWVJRTZvZ3FwN2M3aHRESW5iVkpFelpMYld3?oc=5","date":"2025-10-21","type":"trial","source":"PharmaTimes","summary":"Nxera and Cancer Research UK share promising phase 1 cancer trial results - PharmaTimes","headline":"Nxera and Cancer Research UK share promising phase 1 cancer trial results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQbnhDaUhINFFqT2RWbU9wRjJONDRqSjdKQ2dHUHY0Uk1GMU84NEx5S2x6UTBuRDd4NWFFSF91T2RrZE15UGthVExfOF9vS2VaM3lxVmotYUVXNlpwYjVmNmptZTFSdWtIMWhsS2RjdEJ6OXpvQVpuRHhWYXBzcnhRdUZ1Qk1HdzhUM0pXWG9USHBiM0ZXSlpWRVNLMk9PQk9BbzlHczc2Y9IBrAFBVV95cUxPUXctS3RZZ3FrS2czTUc3eVlab052b24xVnBIQ2dRSTdFMHFjNGV2ODNvby1CWFJTQm5NNk9pd19sMWdwRjZfZWt2UkQwa2JUYWd6WHhtSXI2RUZ1OURXNzhpNHdWc2RKT2w5MnZoTUxNWlduYnRYT0hHekN3c3Jwc2JjTlVKNElQM09abnZrQm41WDdJRXRGTnVlLXZoS1diNHdLOW93eGI2a1BB?oc=5","date":"2025-09-18","type":"trial","source":"Express Pharma","summary":"University of Glasgow study reveals new treatment to prevent breast cancer - Express Pharma","headline":"University of Glasgow study reveals new treatment to prevent breast cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNYXdWUHZ1UnZlQ1pONm42V0ZtM0d4WG1fa0VOY05vWWx4TkhnSUZSd1VHRmJpWXUwYWhIdTlCWE94Z0FBVWtPZDFrRDB1a1VidjNTMVg3eVdoczZfdklTMGxXbWQtU1RJNGFhWG9aQlJwMHJmNTlRZlJwcDI1SWJkODNkU1RybVBrNWUzUjEtbzhXanQtd0dZdk14eVg3UG1xZUpYYlAyS1B1VzlFa294RVB0dmd3UldJV0xvbg?oc=5","date":"2025-09-17","type":"trial","source":"BioPharm International","summary":"Nxera and Cancer Research UK Advance Oral EP4 Antagonist into Phase IIa Study - BioPharm International","headline":"Nxera and Cancer Research UK Advance Oral EP4 Antagonist into Phase IIa Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQZUppanFIV3A2cGlFbFRXaXFGbFREdkctQlBacUp5UmJGRU92SzltdkxKSlBfbkxqT1d3Qk1wRDA1YVdYNkZ3NEt4YXVUWXhsZ1lZQmpUTllrOHFQYmhkMlZINEZoMnVDcDFieHI2ek5TNkJtTHNsN3JIUTZyT0dnaE5nRDJrVzdtclRiYUlqOF9PZmUtdGJFYg?oc=5","date":"2025-09-17","type":"trial","source":"PharmaTimes","summary":"Nxera and Cancer Research UK begin phase 2a trial of HTL0039732 - PharmaTimes","headline":"Nxera and Cancer Research UK begin phase 2a trial of HTL0039732","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxQMGVYSk5EVUZHOGJBOU9nTjJyczNnOE9ad1VJYXNVS0hQR0h5VnRYRlVlWDJJMU1OX0N1MGRKb05Uc2p4VVpEb09iWEdOd1loNUJaQ21Ed2haY00wMFZxRnhCY1NfbWhWWjM2QXRxU2dfNlJ6cHR6NDhhZ2w0dlR0aG52YVIyN1lVRkdELVJRSi01RkZCVU96R205d1VmaHdzMi1uS1Q3SlJiaXRvcFlQM1QxQ1pXZV9GMzlTWmR6U2JhQW9sYnFaSmNfdUZpTXlqNlI3eWpLTF9UajRzTXdESW9WUXFxanBpYjNib3RZN29YMW1fVDZzMDR4Wi1PU2xZSVZac3RObjZsNHVWNUh1Vl9tcFFPRUZTTTlFWHY0bVBIRXFKRGZiVkJybVJPdw?oc=5","date":"2025-09-16","type":"pipeline","source":"GlobeNewswire","summary":"Nxera Pharma and Cancer Research UK Announce First Patient - GlobeNewswire","headline":"Nxera Pharma and Cancer Research UK Announce First Patient","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQcXFCSUJPeUY2QUhfSWRDS3BMU3Q2VldGVk5RRjVnWXVwcWF5U1hYbmJlODB2MVlLNUh0RWl3VU5rLXZpYWNZRGtodXdIdDBmcnhYUUxtdkZlMDBoQ2pkbWV6YUpMZEFnOXVQd3ZTRldNZkF2dk16REdoa1JWYWJSMnVqRUliX3pVR2p5bXRmZ2oySHZHcnRWTGllUXlXakt0eFFISncxeU1ZUkJxMS0zVWU2OElXMGg1?oc=5","date":"2025-09-16","type":"trial","source":"Business Weekly","summary":"Nxera and Cancer Research UK advance trials of advanced solid tumour treatment - Business Weekly","headline":"Nxera and Cancer Research UK advance trials of advanced solid tumour treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBWcGpjNmZyUjQyTkZ3Q0dvOW1DakJKYjdiMHpoeTdqZktPZ2t0UnNqVGlyREo1Y2NlUWdTSXNZY0UzcDZrcnhBWUhCTnlwSFZ6RTJR?oc=5","date":"2025-05-02","type":"pipeline","source":"FirstWord Pharma","summary":"UK hopes planned £1B cancer research hub will attract biotechs - FirstWord Pharma","headline":"UK hopes planned £1B cancer research hub will attract biotechs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNenJ5OUkzY0h4Vm9CWlFNOEVoVjhpa1dDVVhiZUsxaWVoUWhUSzFxVE9CWFFLWDZ1MUgzLWVaRVIwd3VqeDRxcnlBTGh6Z2hjWEU2MUhobWVLdWlJNG00X2dhY2I4ekNXaXpRVmRMbjcxS2ptb0VIRUtLQzNDdkNCNHlWQkFueXNweGJBdFFFb0phNHFMRmV2UQ?oc=5","date":"2024-09-11","type":"pipeline","source":"The Medicine Maker","summary":"Let’s Make a Real Difference in Cancer - The Medicine Maker","headline":"Let’s Make a Real Difference in Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOMndUZ0c3Wm5sQUZfVGh1QmUtWHRwdERTSEpySi03TFBvV3Rfbkt2SUs0MWMzR0FSUXhkMmtvVEgxOEM1SU5MNTNNeTVCM0ppRmF0WFVDV2U1LWozMVM0MGZTYnAxRHFqeGFvQmdaa181STZZT25IN3lfZmxucGJpUDVSMGNkRllZem1JVlI1Ylh0Qy0yMVZPWW5nUUh3c0VnSFEzdmZDS2VzZEJhc0FLNVI5Z2k?oc=5","date":"2014-12-17","type":"pipeline","source":"Cancer Research UK - Cancer News","summary":"Dances with Pharma: part 2 – How Cancer Research UK works with industry - Cancer Research UK - Cancer News","headline":"Dances with Pharma: part 2 – How Cancer Research UK works with industry - Cancer Research UK","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_1":5,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}